Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

This study has been completed.
Information provided by:
CSL Behring
ClinicalTrials.gov Identifier:
First received: September 12, 2005
Last updated: February 10, 2011
Last verified: February 2011

The purpose of this study is to demonstrate the effect of IVIG-F10 on the prevention of serious bacterial infections in patients with primary immunodeficiency.

As secondary endpoints the rate of overall infections, the tolerability and safety of IVIG-F10 are studied.

Condition Intervention Phase
IgG Deficiency
Common Variable Immunodeficiency
Drug: Immunoglobulins Intravenous (Human)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID)

Resource links provided by NLM:

Further study details as provided by CSL Behring:

Primary Outcome Measures:
  • Proportion of infusions temporally (during the infusion and within 48 hours after the end of infusion) associated with one or more adverse events, regardless of relationship.

Secondary Outcome Measures:
  • Rate of acute serious bacterial infections
  • Number of days out of work/school due to underlying PID
  • Number of infections
  • Rate, severity and relationship of all adverse events

Estimated Enrollment: 42
Study Start Date: September 2004
Study Completion Date: September 2005

Ages Eligible for Study:   3 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Patients with primary immunodeficiency
  • Regular IVIG therapy for at least 6 months prior to receiving IVIG-F10

Key Exclusion Criteria:

  • Allergic reactions to immunoglobulins or other blood products
  • Steroids (oral and parenteral, daily ≥0.15 mg of prednisone equivalent/kg/day
  • History of cardiac insufficiency
  • Epilepsia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00168012     History of Changes
Other Study ID Numbers: ZLB04_005CR 
Study First Received: September 12, 2005
Last Updated: February 10, 2011
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by CSL Behring:
Immunoglobulin intravenous
Common variable immunodeficiency
Immunoglobulin G

Additional relevant MeSH terms:
Common Variable Immunodeficiency
IgG Deficiency
Immunologic Deficiency Syndromes
Blood Protein Disorders
Hematologic Diseases
Immune System Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016